ArticleFrontiers in cardiovascular medicine2026
Systemic immune-inflammation index as a prognostic marker in heart failure with non-dialysis chronic kidney disease: a two-cohort derivation and validation study with head-to-head comparison against natriuretic peptides.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Heart failure (HF) and chronic kidney disease (CKD) frequently coexist and share chronic low-grade inflammation, oxidative stress, and thrombotic activation. Natriuretic peptides remain the cornerstone of HF prognostication, but their interpretation is confounded by reduced renal clearance, leading to false elevations and attenuated prognostic specificity in CKD. The systemic immune-inflammation index (SII), derived from routine blood counts, integrates neutrophil-driven inflammation, lymphocyte-mediated immunity, and platelet-associated thrombosis, and may provide a renal-function-independent adjunct to natriuretic peptides among patients with non-dialysis CKD. We aimed to evaluate whether SII provides incremental prognostic information to BNP and NT-proBNP in HF, with particular attention to the non-dialysis cardiorenal spectrum. Methods: We conducted a two-cohort study. The derivation cohort included 1,284 adults hospitalized for chronic HF at Guangdong Medical University Affiliated Hospital (2018-2023). The external validation cohort comprised adults with a first HF hospitalization from MIMIC-IV v3.1 (2008-2022). After excluding patients without SII data and those with incomplete covariates, 11,767 patients were included in the primary analysis. The systemic immune-inflammation index (SII), a composite inflammatory marker derived from routine complete blood count, was calculated as platelet count (×10 Results: SII predicted mortality in the derivation cohort (HR 1.012, 95% CI 1.007-1.017, Conclusion: SII is an inexpensive, universally available prognostic marker in HF patients with non-dialysis CKD. It does not replace NT-proBNP, but provides a statistically significant yet clinically modest incremental signal in CKD-across the non-dialysis CKD spectrum. SII may serve as a practical adjunct, not a substitute, for risk stratification across the non-dialysis cardiorenal spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.